Cyclacel Pharmaceuticals, Inc. (Cyclacel) is a development-stage biopharmaceutical company engaged in the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. The Company markets, directly in the United States, Xclair Cream for radiation dermatitis, and Numoisyn Liquid and Numoisyn Lozenges for xerostomia through its wholly owned subsidiary, ALIGN Pharmaceuticals, LLC (ALIGN). Cyclacel focuses primarily on the development of orally available anticancer agents that target the cell cycle with the aim of slowing the progression or shrinking the size of tumors. The Company has been focusing on the cell cycle since its inception. On January 13, 2009, it announced that the Company began treating patients in a Phase II, open label, single arm, multicenter clinical trial of sapacitabine in patients with non-small cell lung cancer (NSCLC) who have had one prior chemotherapy.Company Contact
| Headquarters:200 Connell Drive suite 1500 Berkeley Heights, NJ 07922 | |
| Web Address: http://www.cyclacel.com |
No comments:
Post a Comment